Patents Assigned to Vanda Pharmaceuticals, Inc.
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 9987264
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 5, 2018
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Treatment of circadian rhythm disorders
    Patent number: 9855241
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 2, 2018
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9850199
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 26, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Treatment of circadian rhythm disorders
    Patent number: 9730910
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: August 15, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone
    Patent number: 9708291
    Abstract: The present invention relates to novel compounds, (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone benzoate, and (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone toluate, which are useful intermediates for the preparation of the compound of Formula I: The present invention further relates to novel processes for preparing a crystalline compound, which is {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, Form IV.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 18, 2017
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Michael Edward Kobierski, Michael E. Kopach, Pingyun Chen
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9617203
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 11, 2017
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Treatment of circadian rhythm disorders
    Patent number: 9549913
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: January 24, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Treatment of circadian rhythm disorders
    Patent number: 9539234
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 10, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Antipsychotic treatment based on SNP genotype
    Patent number: 9458507
    Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: October 4, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Method and composition for treating a serotonin receptor-mediated condition
    Patent number: 9446038
    Abstract: A method and composition for treating serotonin receptor-mediated conditions.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 20, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
  • Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
    Patent number: 9408839
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Grant
    Filed: December 12, 2015
    Date of Patent: August 9, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi
  • TREATING NEURODEGENERATIVE DISEASE WITH FENOFIBRATE AND ANALOGS THEREOF
    Publication number: 20160220523
    Abstract: Provided herein are methods of treating or preventing a neurodegenerative by administering fenofibrate or an analog thereof.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 4, 2016
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael Polymeropoulos, Howard J. Federoff, Xiaomin Su
  • Antipsychotic treatment based on SNP genotype
    Patent number: 9328387
    Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: May 3, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
    Patent number: 9243295
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 26, 2016
    Assignee: Vanda Pharmaceutical, Inc.
    Inventors: Christian Lavedan, Simona Volpi
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9212129
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 15, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent number: 9157121
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: October 13, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Methods for the administration of iloperidone
    Patent number: 9138432
    Abstract: The present invention relates to methods for treating a patient with iloperidone or a metabolite thereof, which patient is also being treated with fluoxetine, and lowering risk for QT prolongation.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 22, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos
  • Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
    Patent number: 9080214
    Abstract: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
    Type: Grant
    Filed: May 17, 2008
    Date of Patent: July 14, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9072742
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Treatment of circadian rhythm disorders
    Patent number: RE46604
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: November 14, 2017
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos